Genmab (GMAB) said Monday that the European Commission approved Tepkinly in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma.
The approval was backed by the phase 3 trial, in which the combination reduced the risk of disease progression or death by 79% and achieved a 96% overall response rate, versus 81% for lenalidomide and rituximab alone.
Genmab said the combination is the first bispecific antibody-based therapy approved in Europe for second-line relapsed or refractory follicular lymphoma and offers a chemotherapy-free treatment option.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments